Market entry for orphan drugs in Switzerland: holder, product information, distribution and listing
Bringing an orphan drug to Switzerland needs a Swiss-domiciled marketing authorisation holder, product information in German, French and Italian, a working pharmacovigilance system, distribution and, for reimbursement, a listing in the specialities list.
Why a Swiss-domiciled authorisation holder is needed
The orphan drug status application itself requires no Swiss establishment. A marketing authorisation is different: the holder is the addressee of the Swissmedic decision and carries the obligations that follow from it, which is why market entry is normally built around a marketing authorisation holder domiciled in Switzerland.
For the status application by contrast no manufacturing, import or wholesale licence and no registered office in Switzerland are required, only an invoice address and a Swiss address for postal deliveries. Confusing the two requirements is a frequent cause of lost time early in a project.
The language requirement for the product information
Switzerland has three official languages in this context and the product information has to be available in German, French and Italian. For an orphan drug this is not a mechanical translation task: the indication wording, which Swissmedic scrutinises against the disease entity, has to say the same thing in all three versions.
- Product information in German, French and Italian.
- Consistent indication wording across all three language versions.
- Terminology aligned with the orphan disease wording on which the status was granted.
- Translation planned into the authorisation timeline, not added after the decision.
The three versions also have to be maintained over the lifecycle. Every variation that touches the product information touches it three times, which is one of the reasons variation fees, payable since 1 January 2019, add up faster than expected.
Pharmacovigilance, distribution and logistics
Once authorised, the product needs the operational structures of any authorised medicine in Switzerland: a pharmacovigilance system with a responsible contact, and a distribution and logistics chain that reaches hospitals and pharmacies. For orphan drugs volumes are small and the number of treating centres is limited, which changes the logistics problem.
Small volumes do not mean small obligations. Reporting duties, batch traceability and supply continuity apply in full, and with a handful of treating centres a single logistics failure can interrupt treatment for a measurable share of all patients on the product in Switzerland.
- Pharmacovigilance: signal handling and reporting obligations towards Swissmedic.
- Distribution: supply to the limited number of treating centres rather than broad retail coverage.
- Logistics: small volumes, often with specific storage and handling requirements.
- Notification duties: changes to the status abroad must be reported to Swissmedic immediately under Art. 5 para. 2 TPLO.
Reimbursement: listing or individual cases
Authorisation does not create reimbursement. Compulsory health insurance pays for a medicine listed in the specialities list of the Federal Office of Public Health. Until a listing exists, access runs through individual-case reimbursement under Art. 71a to 71d KVV, where the insurer approves costs after consulting its medical adviser.
| Route | Who decides | Scope | Timing |
|---|---|---|---|
| Specialities list | Federal Office of Public Health | All insured patients within the listing terms | Examination of efficacy, appropriateness and cost-effectiveness |
| Individual case under Art. 71a to 71d KVV | The patient's health insurer | One patient at a time, after special approval | Decision within two weeks of a complete request |
The two routes coexist rather than succeed one another. Even after a listing, use outside the approved product information or outside the limitation attached to the listing continues to run through Art. 71a KVV and needs cost approval from the insurer.
A realistic sequence
The steps overlap rather than following one another cleanly, and the orphan drug status can be secured before the authorisation application because Art. 4 para. 3 TPLO allows it and Swissmedic processes it faster. The sequence below reflects the dependencies rather than a fixed calendar.
- File the orphan drug status application, which needs no Swiss establishment licence or registered office.
- Set up the Swiss marketing authorisation holder and the operational structures that go with it.
- Prepare the authorisation dossier under the simplified procedure of Art. 14 para. 1 let. f TPA and Art. 24 TPLO, using Art. 13 TPA where a foreign authorisation exists.
- Produce the product information in German, French and Italian with consistent indication wording.
- Establish pharmacovigilance and the distribution chain before the authorisation takes effect.
- File for listing in the specialities list, and manage individual-case requests under Art. 71a to 71d KVV in the meantime.
- Request document protection under Art. 11b para. 4 TPA, since Switzerland grants no market exclusivity.
The critical dependency is the Swiss holder. Almost everything after the status application, from the product information to pharmacovigilance and the listing request, presupposes an entity in Switzerland that can act as marketing authorisation holder.
Costs to budget for
The fee relief that comes with orphan drug status is limited to the flat-rate fee for the new authorisation application under Art. 9 let. a FeeO-Swissmedic. Everything else follows the ordinary tariff, so a market entry budget for an orphan drug is not materially lighter than for any other product after the initial filing.
- Waived: the flat-rate fee for the new authorisation application under Art. 9 let. a FeeO-Swissmedic (SR 812.214.5).
- Payable: variations, which have been subject to fees since 1 January 2019.
- Payable: the fast-track surcharge, despite the status.
- Ongoing: trilingual product information maintenance, pharmacovigilance, distribution and lifecycle regulatory work.
The publisher is Swiss Orphan Access. This directory presents publicly available Swissmedic data. Swiss Orphan Access handles enquiries about this independent directory. Details are shared with external specialists only by separate agreement.
Frequently asked questions
Is a Swiss company needed to market an orphan drug in Switzerland?
Market entry is normally built around a marketing authorisation holder domiciled in Switzerland, which is the addressee of the Swissmedic decision and carries the resulting obligations. The orphan drug status application itself needs no registered office and no manufacturing, import or wholesale licence.
In which languages must the product information be available?
German, French and Italian. For orphan drugs the indication wording has to be consistent across all three versions and aligned with the orphan disease wording on which the status was granted, so translation belongs in the authorisation timeline rather than after the decision.
How long does it take from status to reimbursement?
There is no single figure, because three decisions stack: the status from Swissmedic, the authorisation under the simplified procedure, and the listing in the specialities list by the Federal Office of Public Health. The status can be obtained first, since Art. 4 para. 3 TPLO allows filing before the authorisation application.
What can patients access before a listing exists?
Individual-case reimbursement under Art. 71a to 71d KVV applies to an authorised medicine that is not on the specialities list. Costs are covered only after special approval by the insurer, which must first consult its medical adviser, and the insurer decides within two weeks of a complete request.
Does orphan drug status make market entry cheaper?
Only modestly. It waives the flat-rate fee for the new authorisation application under Art. 9 let. a FeeO-Swissmedic. Variations have been subject to fees since 1 January 2019 and the fast-track surcharge still applies, so ongoing regulatory, pharmacovigilance and distribution costs are unchanged.